Sector News

Novo Nordisk adds to board of directors

February 24, 2016
Life sciences

Danish pharmaceutical firm Novo Nordisk has elected Brian Daniels as a new member of its board of directors.

He brings over 20 years of pharmaceutical management expertise to the board, having served as director of immunology at MSD and vice president of immunology then senior vice president of global development and medical affairs at Bristol-Myers Squibb.

Currently, Daniels serves as a senior advisor to the Boston Consulting Group and a venture partner for 5AM Venture Management, both of which are based in the US.

In a statement, Novo Nordisk’s board of directors said it had recommended Daniels because of “his extensive experience in clinical development, medical affairs and corporate strategy across a broad range of therapeutic areas”.

Novo Nordisk also announced the re-election of Goran Ando, Jeppe Christiansen, Bruno Angelici, Sylvie Gregoire, Liz Hewitt and Mary Szela to the board of directors.

Source: PMLive

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”